Harry Raftopoulos

Harry Raftopoulos is a seasoned professional in clinical research and oncology, currently serving as Senior Vice President and Head of Oncology at Eikon Therapeutics since April 2023. Prior to this role, Harry was a member of the Scientific Advisory Board at FutuRx from February 2022 to April 2023, providing strategic guidance on project development. Harry's extensive experience includes significant positions at Bayer Pharmaceuticals as Vice President, where responsibilities spanned late-stage oncology development and early development of immuno-oncology portfolios from September 2017 to April 2023. Previously, Harry worked at Merck as a Senior Principal Scientist, leading critical studies, including the successful submission for the accelerated approval of Keytruda. In academia, Harry contributed as an Associate Professor of Medicine at North Shore-LIJ Health System and as an Assistant Professor of Medicine at Columbia University Irving Medical Center. Harry holds an MD and a BS in Human Physiology and Medical Biochemistry from the University of the Witwatersrand.